Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
A

PI3K Inhibitors Are Highly Active in R/R Follicular Lymphoma, New Dosing Strategies May Improve Tolerance Without Sacrificing Efficacy

By Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020 FEATURING Andrew Zelenetz
By Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020 FEATURING Andrew Zelenetz
115 views
March 4, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lymphoma
16:05
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is High Risk MCL and How Should We Treat It

Feat. A. Kumar
21:58
MedNews Week

The Evolving 1L DLBCL Landscape: POLARIX, Novel Agents and Future Di…

Feat. M. Matasar
24:57
MedNews Week

Current Management of Newly Diagnosed DLBCL

Feat. M. Matasar
18:10
SOHO Brazil 2023

2023 SOHO® Brazil: "Moving Beyond CHOP/CHOEP - How Disease Feat…

Feat. A. Moskowitz
38:55
Indy Hematology Review

Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…

Feat. G. Salles
07:46
ASCO 2022 Conference Coverage

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLA…

Feat. M. Matasar
05:16
ASCO 2022 Conference Coverage

ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Stud…

Feat. C. Lee Batlevi
34
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updated Interim Analysis of the Randomiz…

Feat. C. Lee Batlevi
12:32
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021: The Next Wave of Novel Agents in Aggressive B-Cell Lympho…

Feat. G. Salles
10:28
i3 Health

MSKCC 2021 Update on Therapeutic Advances in T-Cell Lymphoma: Subtyp…

Feat. S. Horwitz
24:05
SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Sh…

Feat. D. Straus
11:39
SOHO Highlights: State of the Art and Next Questions

Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chem…

Feat. D. Straus
15:22
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on R/R PTCL: Is There a Single Paradigm Overall? Ca…

Feat. S. Horwitz
21:36
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Newly Diagnosed HL: Is ABVD Chemo Regimen Be…

Feat. D. Straus
09:59
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R cHL: Can We Improve Chemo With ADCs and CPI…

Feat. D. Straus
11:13
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on DLBCL: CAR-T vs. autoHCT for Early Relapsed Dise…

Feat. S. Giralt
22:53
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020

2019 ASH Update on the First-Line Therapy in Follicular Lymphoma: Ri…

Feat. A. Zelenetz
22:19
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020

PI3K Inhibitors Are Highly Active in R/R Follicular Lymphoma, New Do…

Feat. A. Zelenetz
07:09
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Next Questions in DLBCL: New Genetic Classification Based Selection …

Feat. A. Younes
15:47
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Who Is a Candidate for Watch and Wait Therapy in MCL / What Are the …

Feat. A. Kumar
15:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

PI3Ki's in Indolent Lymphoma: Overview of Approved Drugs, Trial…

Feat. A. Zelenetz
15:30
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Marginal Gastric Zone Lymphoma: The Role of Radiation Therapy

Feat. J. Yahalom
28:25
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Does RCHOP Stay the Standard of Care After 6 Cycles in Advanced/R DL…

Feat. A. Younes
13:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of Venetoclax in DLBCL: Efficacy and Safety Results from th…

Feat. A. Zelenetz
11:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin…

Feat. A. Moskowitz
23:38
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Ongoing Efforts to Improve the Safety of CAR T-Cell Therapy: Cytokin…

Feat. B. Santomasso
10:01
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Primary CNS Lymphoma - Clinical Features & Staging, Pretreatment…

Feat. C. Grommes
13:27
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Treatment of Primary CNS Lymphoma: Upfront Regimen, Surgery, Treatme…

Feat. C. Grommes
13:57
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Targeted Therapies in CNS Lymphoma & Salvage Options per NCCN Gu…

Feat. C. Grommes